Nascent Biotech, Inc. (NBIO)
| Market Cap | 51.85K -66.7% |
| Revenue (ttm) | n/a |
| Net Income | -1.92M |
| EPS | -0.01 |
| Shares Out | 172.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,000 |
| Open | 0.0005 |
| Previous Close | 0.0003 |
| Day's Range | 0.0003 - 0.0005 |
| 52-Week Range | 0.000001 - 0.1345 |
| Beta | 1.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Nascent Biotech
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Na... [Read more]
Financial Performance
Financial StatementsNews
Nascent Biotech receives delinquency notification related to delayed filing
Nascent Biotech (NBIO) announced that it has received a written notification from the OTC Markets Group as a result of its failure to file its Quarterly Report on Form 10-Q…
Nascent Biotech recaps presentation at Emerging Growth Conference
Nascent Biotech is pleased to provide an overview of the Company’s presentation at The Emerging Growth Conference on July 18, 2024. NBIO CEO, Sean Carrick, and other Biotechnology Innovators, were…
Nascent Biotech Presents at the July Emerging Growth Conference
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM BEACH, FL / ACCESSWIRE / July 30, 2024 / Nascent Bi...
Nascent Biotech embarks on fresh manufacturing run for pritumumab
Nascent Biotech is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement…
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal a...
Nascent Biotech collaborates with HypoSpray on transdermal delivery system
Nascent Biotech and HypoSpray Pharma announced a collaboration to develop an alternative delivery mechanism for patients who can benefit from Pritumumab, Nascent’s lead monoclonal antibody cancer trea...
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal a...
Nascent Biotech, Manhattan BioSolutions partner to explore pritumumab conjugates
Nascent Biotech has entered into a research collaboration agreement with Manhattan BioSolutions to explore antibody-drug conjugates using Nascent’s lead clinical candidate pritumumab as the tumor-targ...
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the develop...
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
Analysts suggest Nascent Value at $0.60 to $2.84 per share NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a ...
Nascent Biotech completes payment of variable convertible note
Nascent Biotech has completed payment of all outstanding variable convertible debt obligations. On August 30, 2023, the Company and the Noteholder YA II PN, LLC agreed to terms that fully…
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the devel...
Nascent Biotech granted Japanese patent for crossing blood-brain barrier
Nascent Biotech announced the Company has been issued a “Method-of-Use” patent from the Japanese Patent Office for its primary asset, Pritumumab. Specifically, the patent approval is related to PTB’s ...
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
NORTH PALM BEACH, FL / ACCESSWIRE / November 29, 2023 / Nascent Biotech, Inc. (OTC:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the develop...
Nascent Biotech to begin Phase II trials for brain cancer
Nascent Biotech has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical…
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
NORTH PALM BEACH, FL / ACCESSWIRE / August 22, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focu...
Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused...
Nascent Biotech Regains Worldwide Rights for Pritumumab
NORTH PALM BEACH, FL / ACCESSWIRE / May 26, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused...
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused ...
Nascent Biotech submits Phase 2 clinical research protocol to FDA
Nascent Biotech announced that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the…
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focus...
Nascent Biotech completes Phase 1 clinical trial for pritumumab
Nascent Biotech has completed and closed its Phase I clinical trial evaluating safety and tolerance for Pritumumab as a treatment for Primary and Metastatic Brain Cancers. Previous announcements share...
Nascent Announces the Completion of Its Phase1 Clinical Trials
NORTH PALM BEACH, FL / ACCESSWIRE / February 28, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is fo...
Nascent Biotech completes dosing requirement in final cohort of Phase 1 trial
Nascent Biotech announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab as a treatment for Brain Cancer. The…
Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal...